Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons.
HIV
diabetes mellitus
direct-acting antivirals
hepatitis C
sustained virologic response
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
18
06
2020
accepted:
30
09
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
8
1
2021
Statut:
epublish
Résumé
The role of hepatitis C virus (HCV) coinfection and HCV-RNA in the development of diabetes mellitus (DM) in HIV-positive persons remains unclear. Poisson regression was used to compare incidence rates of DM (blood glucose >11.1 mmol/L, HbA1C >6.5% or >48 mmol/mol, starting antidiabetic medicine or physician reported date of DM onset) between current HIV/HCV groups (anti-HCV-negative, spontaneously cleared HCV, chronic untreated HCV, successfully treated HCV, HCV-RNA-positive after HCV treatment). A total of 16 099 persons were included; at baseline 10 091 (62.7%) were HCV-Ab-negative, 722 (4.5%) were spontaneous clearers, 3614 (22.4%) were chronically infected, 912 (5.7%) had been successfully treated, and 760 (4.7%) were HCV-RNA-positive after treatment. During 136 084 person-years of follow-up (PYFU; median [interquartile range], 6.9 [3.6-13.2]), 1108 (6.9%) developed DM (crude incidence rate, 8.1/1000 PYFU; 95% CI, 7.7-8.6). After adjustment, there was no difference between the 5 HCV strata in incidence of DM (global HCV coinfection and HCV cure were not associated with DM in this large study. The biggest modifiable risk factors were hypertension and obesity, and continued efforts to manage such comorbidities should be prioritized.
Sections du résumé
BACKGROUND
BACKGROUND
The role of hepatitis C virus (HCV) coinfection and HCV-RNA in the development of diabetes mellitus (DM) in HIV-positive persons remains unclear.
METHODS
METHODS
Poisson regression was used to compare incidence rates of DM (blood glucose >11.1 mmol/L, HbA1C >6.5% or >48 mmol/mol, starting antidiabetic medicine or physician reported date of DM onset) between current HIV/HCV groups (anti-HCV-negative, spontaneously cleared HCV, chronic untreated HCV, successfully treated HCV, HCV-RNA-positive after HCV treatment).
RESULTS
RESULTS
A total of 16 099 persons were included; at baseline 10 091 (62.7%) were HCV-Ab-negative, 722 (4.5%) were spontaneous clearers, 3614 (22.4%) were chronically infected, 912 (5.7%) had been successfully treated, and 760 (4.7%) were HCV-RNA-positive after treatment. During 136 084 person-years of follow-up (PYFU; median [interquartile range], 6.9 [3.6-13.2]), 1108 (6.9%) developed DM (crude incidence rate, 8.1/1000 PYFU; 95% CI, 7.7-8.6). After adjustment, there was no difference between the 5 HCV strata in incidence of DM (global
CONCLUSIONS
CONCLUSIONS
HCV coinfection and HCV cure were not associated with DM in this large study. The biggest modifiable risk factors were hypertension and obesity, and continued efforts to manage such comorbidities should be prioritized.
Identifiants
pubmed: 33409325
doi: 10.1093/ofid/ofaa470
pii: ofaa470
pmc: PMC7772946
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa470Investigateurs
A Harxhi
(A)
M Losso
(M)
M Kundro
(M)
B Schmied
(B)
R Zangerle
(R)
I Karpov
(I)
A Vassilenko
(A)
D Paduto
(D)
N Clumeck
(N)
S De Wit
(S)
M Delforge
(M)
E Florence
(E)
L Vandekerckhove
(L)
V Hadziosmanovic
(V)
J Begovac
(J)
L Machala
(L)
D Jilich
(D)
D Sedlacek
(D)
G Kronborg
(G)
T Benfield
(T)
J Gerstoft
(J)
T Katzenstein
(T)
C Pedersen
(C)
I S Johansen
(IS)
L Ostergaard
(L)
L Wiese
(L)
N F Moller
(NF)
K Zilmer
(K)
I Aho
(I)
J-P Viard
(JP)
P-M Girard
(PM)
C Pradier
(C)
E Fontas
(E)
C Duvivier
(C)
J Rockstroh
(J)
G Behrens
(G)
O Degen
(O)
H J Stellbrink
(HJ)
J Bogner
(J)
G Fätkenheuer
(G)
N Chkhartishvili
(N)
H Sambatakou
(H)
G Adamis
(G)
N Paissios
(N)
J Szlávik
(J)
M Gottfredsson
(M)
C Kelly
(C)
L Tau
(L)
D Turner
(D)
M Burke
(M)
E Shahar
(E)
G Hassoun
(G)
H Elinav
(H)
M Haouzi
(M)
D Elbirt
(D)
A D'arminio Monforte
(A)
R Esposito
(R)
I Mazeu
(I)
C Mussini
(C)
F Mazzotta
(F)
A Gabbuti
(A)
A Lazzarin
(A)
A Castagna
(A)
N Gianotti
(N)
M Galli
(M)
A Ridolfo
(A)
V Uzdaviniene
(V)
R Matulionyte
(R)
T Staub
(T)
R Hemmer
(R)
S Dragas
(S)
M Stevanovic
(M)
P Reiss
(P)
J Trajanovska
(J)
D H Reikvam
(DH)
A Maeland
(A)
J Bruun
(J)
B Knysz
(B)
J Gasiorowski
(J)
M Inglot
(M)
E Bakowska
(E)
R Flisiak
(R)
A Grzeszczuk
(A)
M Parczewski
(M)
K Maciejewska
(K)
B Aksak-Was
(B)
M Beniowski
(M)
E Mularska
(E)
E Jablonowska
(E)
J Kamerys
(J)
K Wojcik
(K)
I Mozer-Lisewska
(I)
B Rozplochowski
(B)
A Zagalo
(A)
K Mansinho
(K)
F Maltez
(F)
C Oprea
(C)
A Yakovlev
(A)
I Khromova
(I)
E Kuzovatova
(E)
E Borodulina
(E)
E Vdoushkina
(E)
J Ranin
(J)
J Tomazic
(J)
J M Miro
(JM)
M Laguno
(M)
E Martinez
(E)
F Garcia
(F)
J L Blanco
(JL)
M Martinez-Rebollar
(M)
J Mallolas
(J)
P Callau
(P)
J Rojas
(J)
A Inciarta
(A)
S Moreno
(S)
B Clotet
(B)
A Jou
(A)
R Paredes
(R)
J Puig
(J)
J M Llibre
(JM)
J R Santos
(JR)
P Domingo
(P)
M Gutierrez
(M)
G Mateo
(G)
M A Sambeat
(MA)
J M Laporte
(JM)
K Falconer
(K)
A Thalme
(A)
A Sonnerborg
(A)
C J Treutiger
(CJ)
L Flamholc
(L)
A Scherrer
(A)
R Weber
(R)
M Cavassini
(M)
A Calmy
(A)
H Furrer
(H)
M Battegay
(M)
P Schmid
(P)
A Kuznetsova
(A)
J Mikhalik
(J)
M Sluzhynska
(M)
A Milinkovic
(A)
A M Johnson
(AM)
E Simons
(E)
S Edwards
(S)
A Phillips
(A)
M A Johnson
(MA)
A Mocroft
(A)
A Winston
(A)
A Clarke
(A)
C Leen
(C)
I Karpov
(I)
M Losso
(M)
J Lundgren
(J)
J Rockstroh
(J)
I Aho
(I)
L D Rasmussen
(LD)
V Svedhem
(V)
G Wandeler
(G)
C Pradier
(C)
N Chkhartishvili
(N)
R Matulionyte
(R)
C Oprea
(C)
J D Kowalska
(JD)
J Begovac
(J)
J M Miró
(JM)
G Guaraldi
(G)
R Paredes
(R)
G Wandeler
(G)
R Paredes
(R)
O Kirk
(O)
L Peters
(L)
A Bojesen
(A)
D Raben
(D)
E V Hansen
(EV)
D Kristensen
(D)
J F Larsen
(JF)
A H Fischer
(AH)
A Mocroft
(A)
A Phillips
(A)
A Cozzi-Lepri
(A)
S Amele
(S)
A Pelchen-Matthews
(A)
A Roen
(A)
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Clin Infect Dis. 2015 Feb 1;60(3):453-62
pubmed: 25313249
Lancet. 2017 Jun 3;389(10085):2239-2251
pubmed: 28190580
AIDS. 2018 Sep 10;32(14):1995-2004
pubmed: 29912062
Nat Rev Microbiol. 2007 Jun;5(6):453-63
pubmed: 17487147
Clin Infect Dis. 2009 Jul 15;49(2):225-32
pubmed: 19508169
Expert Opin Pharmacother. 2018 Jan;19(1):49-64
pubmed: 29252031
Epidemiology. 2018 May;29(3):431-441
pubmed: 29394189
BMJ. 2015 Sep 04;351:h4672
pubmed: 26341898
Clin Infect Dis. 2020 May 6;70(10):2131-2140
pubmed: 31504296
Dig Liver Dis. 2014 Dec 15;46 Suppl 5:S165-73
pubmed: 25458776
Hepatology. 2017 Aug;66(2):344-356
pubmed: 28109003
Hepatology. 2015 Aug;62(2):355-64
pubmed: 25716707
Diabetes Care. 2008 Jun;31(6):1224-9
pubmed: 18268071
J Int AIDS Soc. 2012 Oct 10;15(2):17426
pubmed: 23078769
Liver Int. 2017 Jul;37(7):950-962
pubmed: 27943508
Gastroenterology. 2016 Jun;150(7):1599-1608
pubmed: 26924097
Lancet HIV. 2019 Feb;6(2):e93-e104
pubmed: 30683625
Hepatology. 2014 Oct;60(4):1139-49
pubmed: 24500979
Euro Surveill. 2018 May;23(21):
pubmed: 29845931
AIDS. 2015 Jun 19;29(10):1205-15
pubmed: 25870984
Clin J Am Soc Nephrol. 2007 Jul;2(4):715-21
pubmed: 17699487
J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70
pubmed: 20700060
Hepatology. 2009 Aug;50(2):393-9
pubmed: 19585614
Clin Infect Dis. 2017 Feb 15;64(4):490-497
pubmed: 28172403
J Infect Dis. 2012 Aug 15;206(4):469-77
pubmed: 22811301
Aliment Pharmacol Ther. 2018 Aug;48(3):281-289
pubmed: 29901821
Clin Sci (Lond). 2020 Mar 13;134(5):529-542
pubmed: 32100852
Rev Gastroenterol Mex. 2020 Apr - Jun;85(2):173-179
pubmed: 31784195
World J Hepatol. 2016 Jan 18;8(2):92-106
pubmed: 26807205